5-Oxoproline reduces non-enzymatic antioxidant defenses in vitro in rat brain

Metabolic Brain Disease

Volumn 22, Issue 1, 2007, Pages 51-65

  Pederzolli, Carolina D ^a   Sgaravatti, Ângela M ^a   Braum, César A ^a   Prestes, Cristina C ^a   Zorzi, Giovanni K ^a   Sgarbi, Mirian B ^a   Wyse, Angela T S ^a   Wannmacher, Clóvis M D ^a   Wajner, Moacir ^a   Dutra Filho, Carlos S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

5 Oxoproline; Antioxidant defenses; Glutathione synthetase deficiency; Oxidative stress; Pyroglutamic acid; Rat brain

Indexed keywords

CARBONYL DERIVATIVE; CATALASE; DICHLOROFLUORESCEIN; GLUTATHIONE PEROXIDASE; PROTEIN; PYROGLUTAMIC ACID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; CEREBELLUM; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; FLUORESCENCE; IN VITRO STUDY; LIPID PEROXIDATION; METABOLITE; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT;

ANIMALS; ANTIOXIDANTS; BRAIN DISEASES, METABOLIC; CATALASE; CEREBELLUM; CEREBRAL CORTEX; GLUTATHIONE PEROXIDASE; GLUTATHIONE SYNTHASE; LIPID PEROXIDATION; OXIDATIVE STRESS; PYRROLIDONECARBOXYLIC ACID; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

RATTUS;

EID: 33847664191     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11011-006-9041-2     Document Type: Article

References (43)

1. Aebi H (1984) Catalase in vitro. Meth Enzymol 105:121-126
2. Aksenov MY, Markesbery WR (2001) Change in thiol content and expression of glutathione redox system gene in the hippocampus and cerebellum in Alzheimer's disease. Neurosci Lett 302:141-145
3. Barone D, Spignoli G (1990) Investigations on the binding properties of the nootropic agent pyroglutamic acid. Drugs Exp Clin Res 16:85-99
4. Bennet Jr JP, Logan WJ, Snyder SH (1973) Amino acids as central nervous transmitters: the influence of ions, amino acid analogues, and ontogeny on transport systems for l-glutamic and aspartic acids and glycine into central nervous synaptosomes. J Neurochem 2:1533-1550
5. Dahl N, Pigg M, Ristoff E, Gali R, Carlsson B, Mannervik B, Larsson A, Board P (1997) Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet 6:1147-1152
6. Dusticier N, Kerkerian L, Errami M, Nieoullon A (1985) Effects of pyroglutamic acid on corticostriatal glutamatergic transmission. Neuropharmacology 24:903-908
7. Eldjarn L, Jellum E, Stokke O (1972) Pyroglutamic aciduria: Studies on the enzymic block and on the metabolic origin of pyroglutamic acid. Clin Chim Acta 48:461-476
8. Eldjarn L, Jellum E, Stokke O (1973) Pyroglutamic aciduria: rate of formation and degradation of pyroglutamate. Clin Chim Acta 49:311-323
9. +-ATPase of small intestine microvilli by pyrrolidone carboxylic acid. Clin Chim Acta 49:147-151
10. Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Meth Enzymol 186:407-421
11. Evelson P, Travacio M, Repetto M, Escobar J, Llesuy SF, Lissi E (2001) Evaluation of total reactive antioxidant potential (TRAP) of tissue homogenates and their cytosols. Arch Biochem Biophys 388:261-266
12. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases. Therapeutic implications for antioxidant treatment. Drug Aging 18:685-716
13. Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in vivo in cell culture: how should you do it and what do the results mean? Brit J Pharmacol 142:231-255
14. Hoffmann GF, Meier-Augenstein W, Stöckler S, Surtees R, Rating D, Nyhan WL (1993) Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inher Metab Dis 16:648-699
15. Jain A, Buist NRM, Kennaway NG, Powell BR, Auld PA, Martensson J (1994) Effect of ascorbate or N-acetylcysteine treatment in a patient with hereditary glutathione synthetase deficiency. J Pediatr 124:229-233
16. Jellum E, Kluge T, Borrensen HC, Stokke O, Eldjarn I (1970) Pyroglutamic aciduria: a new inborn error of metabolism. Scand J Clin Lab Invest 26:327-335
17. Larsson A, Wachtmeister L, von Wendt L, Andersson R, Hagenfeldt L, Herrin KM (1985) Ophtalmological psychometric and therapeutic investigation in two sisterswith hereditary glutathione synthetase deficiency (5-oxoprolinuria). Neuropediatrics 16:131-136
18. Larsson A, Anderson ME (2001) Glutathione synthetase deficiency and other disorders of the γ-glutamyl cycle. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds), The metabolic andmolecular bases of inherited disease. McGraw-Hill, New York, pp 2205-2216
19. Lissi E, Caceres T, Videla LA (1986) Visible chemiluminescence from rat brain homogenates undergoing autoxidation. I effect of additives and products accumulation. Free Radic Biol Med 2:63-69
20. Lissi E, Pascual C, Del Castillo MD (1992) Luminol luminescence induced by 2,2′-azo-bis-(2-amidinopropane) thermolysis. Free Radic Res Commun 17:299-311
21. Lissi E, Salim-Hanna M, Pascual C, Del Castillo MD (1995) Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence measurements. Free Radic Biol Med 18:153-158
22. Llesuy SF, Milei J, Molina H, Boveris A, Milei S (1985) Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4′-epiadriamycin in mice. Tumori 71:241-249
23. Lowry OH, Rosebrough NJ, Lewis-Farr A, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
24. Marklund SL (1985) Pyrogallol autoxidation in handbook for oxygen radical research. CRC Press, Boca Raton, pp 243-247
25. Marstein S, Jellum E, Nesbakken R, Perry TL (1981) Biochemical investigations of biopsied brain tissue and autopsied organs from a patient with pyroglutamic acidemia (5-oxoprolinemia). Clin Chim Acta 111:219-228
26. Meister A (1974) The γ-glutamyl cycle diseases associated with specific deficiencies. Annals Intern Med 81:247-253
27. Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51:155-194
28. Myhre O, Andersen JM, Aarnes H, Fonnum F (2003) Evaluation of the probes 2′,7′-dichlorofluorescin diacetate luminol and lucigenin as indicators of reactive species formation. Biochem Pharmacol 65:1575-1582
29. Nicholls DG, Budd SL (1998) Mitochondria and neuronal glutamate excitotoxicity. Biochim Biophys Acta 1366:97-112
30. Njalsson R (2005) Glutathione synthetase deficiency. Cell Mol Life Sci 62:1938-1945
31. Njalsson R, Norgren S (2005) Physiological and pathological aspects of GSH metabolism. Acta Paediatr 94:132-137
32. Njalsson R, Ristoff E, Carlsson K, Winkler A, Larsson A, Norgren S (2005) Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency. Hum Genet 116:384-389
33. Oyama Y, Hayashi A, Ueha T, Maekawa K (1994) Characterization of 2′-7′-dichlorofluorescin fluorescence in dissociated mammalian brain neurons: Estimation on intracellular content of hydrogen peroxide. Brain Res 635:113-117
34. Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Meth Enzymol 233:357-363
35. Rieke GK, Scarfe AD, Hunter JF (1984) l-pyroglutamate: an alternate neurotoxin for a rodent model of Huntington's Disease. Brain Res Bull 13:443-456
36. Rieke GK, Smith J, Idusuyi OB, Semenya J, Howard R (1989) Chronic intrastriatal l-pyroglutamate: neuropathology and neuron sparing like Huntington's disease. Exp Neurol 104:147-154
37. Ristoff E, Mayatepek E, Larsson A (2001) Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr 139:79-84
38. Rothstein JD, Jin L, Dykes-Hoberg M, Kunet RCU (1993) Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 90:6591-6595
39. Silva AR, Silva CG, Ruschel C, Helegda C, Wyse ATS, Wannmacher CMD, Wajner M, Dutra-Filho CS (2001) l-Pyroglutamic acid inhibits energy production and lipid synthesis in cerebral cortex of young rats in vitro. Neurochem Res 26:1277-1283
40. Skullerud K, Marstein S, Schrader H, Brundelet PJ, Jellum E (1980) The cerebral lesions in a patient with generalized glutathione deficiency and pyroglutamic aciduria (5-oxoprolinuria). Acta Neuropathol 52:235-238
41. Stadtman EA (1990) Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 9:315-325
42. Wardman P, Burkitt MJ, Patel KB, Lawrence A, Jones CM, Everett SA, Vojnovic B (2002) Pitfalls in the use of common luminescent probes for oxidative and nitrosative species. J Fluores 12:65-68
43. Wendel A (1981) Glutathione peroxidase. Meth Enzymol 77:325-332